Latest Healthcare Sector News

dorsaVi reports breakthrough RRAM sensor performance and secures a major US physical therapy deal, backed by a $5 million capital raise and new leadership appointments.

Anatara Lifesciences reports steady progress in its anti-obesity pre-clinical studies with results expected by year-end, while preparing its GaRP gastrointestinal health data for publication amid ongoing commercial talks. The company also announces a key board appointment and a $1.2 million capital raise.

Australian Clinical Labs has announced a 12-month on-market share buy-back program targeting up to 10% of its shares, aiming to enhance shareholder returns without compromising its financial strength.

Beam Dental Bidco Pty Ltd has secured a 99.31% stake in Pacific Smiles Group Limited and is set to compulsorily acquire the remaining shares at $2.20 each. The takeover offer closes on 17 November 2025 with no extension planned.

Wellnex Life Limited announces the resignation of CEO Zack Bozinovski, who will remain with the company until April 2026, while a $2.3 million loan repayment schedule is negotiated.

Ramsay Health Care announces a fully franked ordinary distribution of AUD 2.9642 per security on its perpetual preference shares, reflecting a steady income stream for investors. The payment is scheduled for April 2026, subject to board and external approvals.

EPX Limited reported a net increase in Annual Contract Value to $18 million and a steady rise in Annual Recurring Revenue to $15.7 million for Q3 2025, driven by new contracts in the UAE healthcare sector and Australian commercial properties.

Wellnex Life reported an 18.2% sales decline in Q1 FY26 amid delayed IP licensing revenue and increased costs, while securing new debt facilities and exiting the medicinal cannabis segment.

Alcidion Group Limited has reported a record FY25 with strong revenue growth, major NHS contract wins, and expanded AI capabilities in its Miya Precision platform, setting the stage for global healthcare IT expansion.

Aroa Biosurgery delivered a robust September quarter with strong cash flow and record sales of its Myriad product, while reaffirming its FY26 revenue and EBITDA guidance. The company also highlighted a promising US Medicare reimbursement proposal for its Symphony product.

Cann Group Limited has extended the expiry of its National Australia Bank debt facilities by one year to October 2025, maintaining current terms while exploring long-term refinancing options.

333D Ltd reports a fifth consecutive quarter of revenue growth, secures $1 million in fresh capital, and expands its blockchain healthcare initiatives while building a strategic Bitcoin treasury.